Psychiatr. pro Praxi, 2006; 3: 112-116

Pharmacotherapy of anxiety disorders

MUDr. Sylva Racková, MUDr. Luboš Janů Ph.D
Psychiatrická klinika FN a LF UK v Plzni

Anxiety disorders are very often psychiatric disorders. Without treatment mostly anxiety sypmtoms persist, their course is very often chronical with fluctuation and high risk of the presence of comorbide disorders, suicidal behaviour… In the treatment of anxiety disorders we can use psychotheraphy and pharmacotheraphy. There are antidepressant of the 3rd or the 4th generation the first choice in the psychopharmacotheraphy. Other medication witch is used in the treatment of these disorders are benzodiazepines, betablockers, anticonvulsives.

Keywords: anxiety disorders, pharmacotheraphy, antidepressants, benzodiazepines

Published: July 1, 2006  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Racková S, Janů L. Pharmacotherapy of anxiety disorders. Psychiatr. praxi. 2006;7(3):112-116.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Ballenger JC. Panic disorder and agoraphobia. In: MG Geodet, JJ Polez-Ibor, N. Andreasen: New Oxford Textbook of Psychiatry, Oxford University Press. Oxford, 2000; 807-822.
    2. Ballenger JC. Selective serotonin reuptake inhibitors (SSRIs) in panic disorder. In: Nutt D, Ballenger J, Lepine JP. Panic disorder: clinical diagnosis, management and mechanism. London, Dunitz, 1999; 159-178.
    3. Boyer W. Serotinine uptame inhibitors are superior to imipramine and alprazolam in alleviating panic attacks: meta-analysis, Int Clin Psychopharmacol, 1995; 10: 45-49. Go to original source... Go to PubMed...
    4. Brady KT, Lydiard RB. The association of alcoholism and anxiety, Psychiatr Q, 1993; 64: 135-149. Go to original source... Go to PubMed...
    5. Eaton MW, Kessler RC, Wittchen HU, Magee WJ. Panic and panic disorder in the United States, Am J of Psychiatry, 1994; 151: 413-420. Go to original source... Go to PubMed...
    6. Janicak PG. Handbook of Psychopharmacotheraphy, Philadelphia, Lippincott Williams and Wilkins, 1999: 391.
    7. Kasper S, Loft H, Nil R. Escitalopram in the treatment of social anxiety disorder. 2002; presented at the 54th APA Institute of Psychiatric Services.
    8. Kasper S, Zohar J, Stein DJ. Decision Making in Psychopharmacology. Martin Dunitz London, 2002; 165.
    9. Katching H, Amering M, Stolk JM, Ballenger JC. Predictors of quality of life in a long-therm follow-up study in panic disorders patients after a clinical drug trial. Psychopharmacol Bulletin, 1996; 32: 149-155.
    10. Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S, Wittchen HU, Kendler KS. Lifetime and 12-month prevalence of DSM III-R psychiatric disorders in the United States, Arch Gen Psychiatry, 1994; 51: 8-19. Go to original source... Go to PubMed...
    11. Lepola U, Wade AG, Leihonen EV. A controlled one year trial with citalopram in the treatment of panic disorder, J Clin Psychiatry, 1998; 59: 528-534. Go to original source... Go to PubMed...
    12. Mavissakalian M, Perel JM. Protective effects of imipramine maintenance treatment in panic disorder with agoraphobia, Am J Psychiatry, 1992; 149: 1053-1057. Go to original source... Go to PubMed...
    13. Narrow WE, Rae DS, Robins LN, Regier DA. Revised prevalence estimates of mental disordersit the United States: using a clinical significance criterion to reconsile 2 surveys´ estimates, Arch Gen Psychiatry, 2002, 59: 115-123. Go to original source... Go to PubMed...
    14. Pollack MH, Matthews J, Scott EL. Gabapentine as a potential treatment for anxiety disorders, Am J Psychiatry, 1998; 155: 992-993. Go to original source... Go to PubMed...
    15. Praško J, Prašková H. Farmakoterapie úzkostných poruch, Remedia, 2005; 495-508.
    16. Praško J a kol. Panická porucha, Agorafobie, Generalizovaná úzkostná porucha, Sociální fobie, Specifické fobie, Smíšená úzkostně depresivní porucha, In: Seifertová D, Praško J, Hoschl C: Postupy v léčbě psychických poruch, Praha, Academia Medica Pragensis, 2004; 139-251.
    17. Prašková H, Praško J. Úzkostné a fobické poruchy, Praha, Galén, 2000.
    18. Regier D, Narrow W, Rae D, Manderscheid R, Locke B, Goodwin F. The de facto US mental and addictive disorders service system, Arch Gen Psychiatry, 1993; 50: 85-94. Go to original source... Go to PubMed...
    19. Tesar GE, Rosenbaum JF. Successful use of clonazepam in patients with treatment-resistant panic disorder. J Nerv Ment Dis, 1986; 174: 477-482. Go to original source... Go to PubMed...
    20. Tiffon L, Coplan JD, Papp LA. Augmentation strategies with tricyclic or fluoxetine treatment in seven partially responsive panic disorder patients, J Clin Psychiatry, 1994; 55: 66-69.
    21. Weissman MM, Bland RC, Canino GJ. The Gross-national epidemiology of panic disorder, Arch Gen Psychiatry; 1997; 54: 305-309. Go to original source... Go to PubMed...
    22. Weissman MM, Klerman GL, Markowitz JS. Suicidal ideation and suicide attempts in panic disorder and attacks, N Engl J Med, 1989; 321: 1209-1214. Go to original source... Go to PubMed...

    Return to the content


    Psychiatry for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.